Maze Therapeutics, Inc. (MAZE) shareholders
Close on Nov 17, 2026Market cap $1.83BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Third Rock Ventures IV, L.P. Joint filing with Third Rock Ventures GP IV, L.P. (13.90%), Trv Gp Iv, LLC (13.90%) | 6,073,958 | 13.90% | 13G (passive) | Jan 31, 2025 |
| Third Rock Ventures GP IV, L.P. Joint filing with Third Rock Ventures IV, L.P. (9.30%), Trv Gp Iv, LLC (9.30%) | 4,473,958 | 9.30% | 13G (passive) amendment | Dec 31, 2025 |
| James N. Topper Joint filing with Patrick J. Heron (10.20%), Albert Cha (9.70%) and 4 more | 4,451,339 | 10.20% | 13G (passive) amendment | Apr 25, 2025 |
| Fhmlsp, L.P. Joint filing with Frazier Life Sciences Public Fund, L.P. (9.00%), Fhmlsp, L.L.C. (9.00%) | 4,342,266 | 9.00% | 13G (passive) amendment | Dec 31, 2025 |
| Patrick J. Heron Joint filing with James N. Topper (9.40%), Albert Cha (9.00%) and 4 more | 4,129,000 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| Kristina Burow Joint filing with ARCH Venture Fund X, L.P. (9.40%), ARCH Venture Fund X Overage, L.P. (9.40%) and 6 more | 4,120,053 | 9.40% | 13G (passive) | Mar 31, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (9.02%), David Kroin (9.02%) | 3,948,910 | 9.02% | 13G (passive) amendment | Jun 30, 2025 |
| Fhmlsp, L.L.C. Joint filing with Frazier Life Sciences Public Fund, L.P. (7.70%), Fhmlsp, L.P. (7.70%) | 3,352,915 | 7.70% | 13G (passive) amendment | Jun 30, 2025 |
| David Kroin Joint filing with Deep Track Capital, LP (6.91%), Deep Track Biotechnology Master Fund, Ltd. (6.91%) | 3,023,484 | 6.91% | 13G (passive) | Jan 31, 2025 |
| BlackRock, Inc. | 2,978,114 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Janus Henderson Group PLC | 2,858,876 | 5.80% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MAZE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,032,915 | 9.06% | $150.18M | +465,641 | 3.27% |
| Trv Gp Iv, LLC | 4,473,958 | 8.05% | $133.50M | – | 52.63% |
| ARCH Venture Management, LLC | 4,120,053 | 7.42% | $122.98M | – | 11.18% |
| Deep Track Capital, LP | 3,732,569 | 6.72% | $111.38M | +255,007 | 1.62% |
| BlackRock, Inc. | 3,502,841 | 6.31% | $104.52M | +932,416 | 0.00% |
| Jupiter Topco LLC | 3,408,045 | 6.14% | $101.76M | New | 0.04% |
| T. Rowe Price Investment Management, Inc. | 2,603,682 | 4.69% | $77.69M | New | 0.05% |
| Logos Global Management LP | 1,935,000 | 3.48% | $57.74M | +700,000 | 2.49% |
| Vanguard Capital Management LLC | 1,778,222 | 3.20% | $53.06M | +342,566 | 0.00% |
| a16z Capital Management, L.L.C. | 1,702,225 | 3.06% | $50.79M | – | 0.36% |
| VR Adviser, LLC | 1,602,034 | 2.88% | $47.80M | – | 1.45% |
| Alphabet Inc. | 1,388,583 | 2.50% | $41.44M | – | 0.04% |
| Braidwell LP | 1,140,040 | 2.05% | $34.02M | New | 1.26% |
| Farallon Capital Management LLC | 1,107,814 | 1.99% | $33.06M | +734,814 | 0.15% |
| FMR LLC | 1,056,959 | 1.90% | $31.54M | +192,745 | 0.00% |
| General Catalyst Group Management, LLC | 1,035,910 | 1.86% | $30.91M | – | 16.40% |
| State Street Corp | 997,533 | 1.80% | $29.77M | +360,811 | 0.00% |
| JPMorgan Chase & Co | 964,011 | 1.74% | $28.00M | +905,565 | 0.00% |
| Driehaus Capital Management LLC | 954,886 | 1.72% | $28.49M | +318,724 | 0.17% |
| Trv Gp V, LLC | 950,800 | 1.71% | $28.37M | – | 5.69% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 162 | 59M | 100.0% | 39 / 66 | 38 / 39 | 17M | 8M |
| Q1 2026 | 165 | 52M | 93.0% | 49 / 58 | 36 / 25 | 11M | 6M |
| Q4 2025 | 143 | 48M | 87.1% | 57 / 46 | 20 / 8 | 10M | 5M |
| Q3 2025 | 94 | 43M | 77.4% | 23 / 39 | 15 / 3 | 8M | 4M |
| Q2 2025 | 75 | 39M | 69.9% | 14 / 25 | 14 / 7 | 2M | 3M |
| Q1 2025 | 68 | 40M | 72.1% | 68 / 0 | 0 / 0 | 40M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
174 funds held MAZE in Q2 2026, 46% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MAZE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,411,990 | 2.54% | $42.13M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 978,329 | 1.76% | $29.19M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 920,284 | 1.66% | $27.46M | 0.03% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 739,660 | 1.33% | $19.57M | 0.37% | May 31, 2026 |
| JPMorgan Small Cap Growth Fund | 421,350 | 0.76% | $12.57M | 0.48% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 385,642 | 0.69% | $10.38M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 325,513 | 0.59% | $9.71M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 295,465 | 0.53% | $8.82M | 0.09% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 276,075 | 0.50% | $8.24M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 274,185 | 0.49% | $8.18M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 265,830 | 0.48% | $7.93M | 1.85% | Jun 30, 2026 |
| iShares Biotechnology ETF | 242,763 | 0.44% | $7.24M | 0.08% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 212,255 | 0.38% | $6.33M | 0.04% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 184,453 | 0.33% | $4.88M | 0.08% | May 29, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 158,415 | 0.29% | $4.73M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jason V. Coloma | Chief Executive Officer, Director | 227,228 | 0.41% | Nov 4, 2026 |
| Atul Dandekar | CSBO | 32,316 | 0.06% | Oct 30, 2026 |
| Harold Bernstein | President, R&D & CMO | 0 | – | Oct 2, 2026 |
| Phillips Courtney | GC and Corp. Secretary | 7,007 | 0.01% | Sep 4, 2026 |
| Amy Bachrodt | SVP, Finance | 15,465 | 0.03% | Apr 2, 2026 |
| Misbah Tahir | Chief Financial Officer | – | – | Mar 3, 2026 |
| Paula A. Johnson | Director | – | – | Aug 17, 2026 |
| Sophie Kornowski | Director | – | – | Aug 17, 2026 |
| Richard H. Scheller | Director | 0 | – | Jun 10, 2026 |
| Herve Hoppenot | Director | – | – | Jun 10, 2026 |
| Jonathan E. Lim | Director | 328,700 | 0.59% | Jun 10, 2026 |
| Daniel K. Spiegelman | Director | – | – | Jun 10, 2026 |
| Charles J. Homcy | Director | 38,535 | 0.07% | Jun 10, 2026 |
| Nancy C. Andrews | Director | – | – | Jun 10, 2026 |
| Neil Kumar | Director | – | – | Mar 31, 2026 |
| Catherine A. Sohn | Director | 20,744 | 0.04% | Jan 8, 2026 |
| Sekar Kathiresan | Director | 103,723 | 0.19% | Sep 24, 2025 |
| Neil Exter | Director | – | – | Sep 24, 2025 |
| James Brush | Director | – | – | Jan 30, 2025 |
| Jeffrey K. Tong | Director | – | – | Jan 30, 2025 |
| Alan Colowick | Director | – | – | Jan 30, 2025 |
| Third Rock Ventures GP V, LP | 10% owner | 5,424,758 | 9.77% | Nov 5, 2025 |
| Third Rock Ventures V, L.P. | 10% owner | – | – | Nov 5, 2025 |
| Third Rock Ventures GP IV, L.P. | 10% owner | – | – | Nov 5, 2025 |
| Trv Gp Iv, Llc | 10% owner | – | – | Nov 5, 2025 |
| Third Rock Ventures IV, L.P. | 10% owner | 7,024,758 | 12.65% | Nov 5, 2025 |
| Trv Gp V, Llc | 10% owner | 311,170 | 0.56% | Nov 5, 2025 |
| Kristina Burow | 10% owner | – | – | Jan 30, 2025 |
| Robert Nelsen | 10% owner | – | – | Jan 30, 2025 |
| Steven Gillis | 10% owner | – | – | Jan 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jason V. Coloma Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −5,345 | $31.05 | $165.98K | 186,901 |
| Jason V. Coloma Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −26,563 | $30.09 | $799.41K | 164,884 |
| Jason V. Coloma Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −336 | $30.91 | $10.39K | 12,965 |
| Jason V. Coloma Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −2,257 | $30.12 | $67.99K | 13,301 |
| Atul Dandekar CSBO | Oct 29, 2026 | Sale(10b5-1 plan) | −7,500 | $32.07 | $240.53K | 32,316 |
| Atul Dandekar CSBO | Oct 29, 2026 | Option exercise | +857 | $10.42 | $8.93K | 39,816 |
| Atul Dandekar CSBO | Oct 29, 2026 | Option exercise | +6,643 | $10.42 | $69.22K | 38,959 |
| Harold Bernstein President, R&D & CMO | Oct 1, 2026 | Sale(10b5-1 plan) | −16,141 | $26.93 | $434.74K | 0 |
| Harold Bernstein President, R&D & CMO | Oct 1, 2026 | Option exercise | +16,141 | $10.42 | $168.19K | 16,141 |
| Jason V. Coloma Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −31,908 | $27.02 | $862.19K | 191,447 |
| Jason V. Coloma Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −2,593 | $27.02 | $70.07K | 15,558 |
| Atul Dandekar CSBO | Sep 29, 2026 | Sale(10b5-1 plan) | −7,500 | $27.06 | $202.92K | 32,316 |
| Atul Dandekar CSBO | Sep 29, 2026 | Option exercise | +7,500 | $10.42 | $78.15K | 39,816 |
| Harold Bernstein President, R&D & CMO | Sep 4, 2026 | Sale(10b5-1 plan) | −9,705 | $26.22 | $254.47K | 0 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 3, 2026 | Sale | −11,282 | $26.01 | $293.44K | 27,491 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 3, 2026 | Sale | −129 | $25.77 | $3.32K | 27,362 |
| Atul Dandekar CSBO | Sep 3, 2026 | Sale | −36 | $25.81 | $929 | 32,316 |
| Atul Dandekar CSBO | Sep 3, 2026 | Sale | −3,207 | $26.01 | $83.41K | 32,352 |
| Phillips Courtney GC and Corp. Secretary | Sep 3, 2026 | Sale | −22 | $25.78 | $567 | 7,007 |
| Phillips Courtney GC and Corp. Secretary | Sep 3, 2026 | Sale | −1,990 | $26.01 | $51.76K | 7,029 |
| Harold Bernstein President, R&D & CMO | Sep 3, 2026 | Sale | −5,130 | $26.01 | $133.43K | 9,764 |
| Harold Bernstein President, R&D & CMO | Sep 3, 2026 | Sale | −59 | $25.78 | $1.52K | 9,705 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 2, 2026 | Sale | −9,852 | $26.38 | $259.90K | 40,148 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 2, 2026 | Sale | −1,375 | $27.12 | $37.29K | 38,773 |
| Atul Dandekar CSBO | Sep 2, 2026 | Sale | −391 | $27.12 | $10.60K | 35,559 |
| Atul Dandekar CSBO | Sep 2, 2026 | Sale | −2,800 | $26.38 | $73.86K | 35,950 |
| Phillips Courtney GC and Corp. Secretary | Sep 2, 2026 | Sale | −1,738 | $26.38 | $45.85K | 9,262 |
| Phillips Courtney GC and Corp. Secretary | Sep 2, 2026 | Sale | −243 | $27.12 | $6.59K | 9,019 |
| Harold Bernstein President, R&D & CMO | Sep 2, 2026 | Sale | −4,481 | $26.38 | $118.21K | 15,519 |
| Harold Bernstein President, R&D & CMO | Sep 2, 2026 | Sale | −625 | $27.12 | $16.95K | 14,894 |
| Atul Dandekar CSBO | Sep 1, 2026 | Option exercise | +12,500 | – | – | 38,750 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −31,908 | $26.29 | $838.86K | 223,355 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 1, 2026 | Option exercise | +50,000 | – | – | 50,000 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −2,593 | $26.31 | $68.22K | 18,151 |
| Phillips Courtney GC and Corp. Secretary | Sep 1, 2026 | Option exercise | +11,000 | – | – | 11,000 |
| Harold Bernstein President, R&D & CMO | Sep 1, 2026 | Option exercise | +20,000 | – | – | 20,000 |
| Harold Bernstein President, R&D & CMO | Sep 1, 2026 | Sale(10b5-1 plan) | −16,141 | $26.36 | $425.48K | 0 |
| Harold Bernstein President, R&D & CMO | Sep 1, 2026 | Option exercise | +16,141 | $10.42 | $168.19K | 16,141 |
| Atul Dandekar CSBO | Aug 28, 2026 | Option exercise | +7,500 | $10.42 | $78.15K | 33,750 |
| Atul Dandekar CSBO | Aug 28, 2026 | Sale(10b5-1 plan) | −7,500 | $27.58 | $206.85K | 26,250 |
| Harold Bernstein President, R&D & CMO | Aug 13, 2026 | Option exercise | +16,142 | $10.42 | $168.20K | 16,142 |
| Harold Bernstein President, R&D & CMO | Aug 13, 2026 | Sale(10b5-1 plan) | −16,142 | $27.61 | $445.68K | 0 |
| Jason V. Coloma Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −1,604 | $27.09 | $43.45K | 255,263 |
| Jason V. Coloma Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −30,304 | $26.71 | $809.42K | 256,867 |
| Jason V. Coloma Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −154 | $27.09 | $4.17K | 20,744 |
| Jason V. Coloma Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −2,439 | $26.71 | $65.15K | 20,898 |
| Atul Dandekar CSBO | Jul 29, 2026 | Sale(10b5-1 plan) | −7,100 | $27.31 | $193.90K | 26,650 |
| Atul Dandekar CSBO | Jul 29, 2026 | Sale(10b5-1 plan) | −400 | $27.89 | $11.16K | 26,250 |
| Atul Dandekar CSBO | Jul 29, 2026 | Option exercise | +7,500 | $10.42 | $78.15K | 33,750 |
| Jason V. Coloma Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −30,311 | $29.95 | $907.81K | 288,768 |
| Jason V. Coloma Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,593 | $29.98 | $77.74K | 23,337 |
| Jason V. Coloma Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,597 | $30.44 | $48.61K | 287,171 |
| Harold Bernstein President, R&D & CMO | Jul 1, 2026 | Sale(10b5-1 plan) | −13,409 | $29.87 | $400.53K | 1,200 |
| Harold Bernstein President, R&D & CMO | Jul 1, 2026 | Option exercise | +14,609 | $10.42 | $152.23K | 14,609 |
| Harold Bernstein President, R&D & CMO | Jul 1, 2026 | Sale(10b5-1 plan) | −1,200 | $30.34 | $36.41K | 0 |
| Atul Dandekar CSBO | Jun 29, 2026 | Option exercise | +7,500 | $10.42 | $78.15K | 33,750 |
| Atul Dandekar CSBO | Jun 29, 2026 | Sale(10b5-1 plan) | −7,500 | $28.02 | $210.15K | 26,250 |
| Jason V. Coloma Chief Executive Officer, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −23,865 | $26.05 | $621.68K | 319,079 |
| Jason V. Coloma Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −2,040 | $26.00 | $53.04K | 25,930 |
| Jason V. Coloma Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −1,953 | $26.00 | $50.78K | 342,944 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Maze Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,859 shares on Sep 16, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jason V. Coloma Officer | Nov 2, 2026 | 34,501 | $1.09M | Nov 2, 2026 | Gift |
| Atul Dandekar Officer | Oct 29, 2026 | 15,000 | $475.95K | Oct 29, 2026 | Exercise of Stock Options |
| Jason V. Coloma Officer | Oct 1, 2026 | 34,501 | $933.25K | Oct 1, 2026 | Gift |
| Harold Bernstein Officer | Oct 1, 2026 | 16,141 | $438.71K | Oct 1, 2026 | Exercise of Stock Options |
| Harold Bernstein Officer | Sep 4, 2026 | 9,705 | $251.07K | Sep 4, 2026 | Restricted Stock Units |
| Phillips Courtney Officer | Sep 2, 2026 | 4,144 | $110.00K | Sep 2, 2026 | Restricted Stock Unit Vesting |
| Atul Dandekar Officer | Sep 2, 2026 | 6,679 | $177.20K | Sep 2, 2026 | Restricted Stock Unit Vesting |
| Jason V. Coloma Officer | Sep 2, 2026 | 23,497 | $623.40K | Sep 2, 2026 | Restricted Stock Unit Vesting |
| Harold Bernstein Officer | Sep 2, 2026 | 10,685 | $283.50K | Sep 2, 2026 | Restricted Stock Unit Vesting |
| Jason V. Coloma Officer | Sep 1, 2026 | 34,501 | $908.07K | Sep 1, 2026 | Gift |
| Jason V. Coloma Officer | Aug 3, 2026 | 34,501 | $922.56K | Aug 3, 2026 | Gift |
| Atul Dandekar Officer | Jul 29, 2026 | 22,500 | $627.30K | Jul 29, 2026 | Exercise of Stock Options |
| Harold Bernstein Officer | Jul 1, 2026 | 46,892 | $1.40M | Jul 1, 2026 | Exercise of Stock Options |
| Jason V. Coloma Officer | Jul 1, 2026 | 34,501 | $1.03M | Jul 1, 2026 | Gift |
| Jason V. Coloma Officer | Jun 1, 2026 | 34,501 | $908.07K | Jun 1, 2026 | Gift |
See a number that looks wrong?